Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Clinical Oncology

• Publication date

  2006-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0169-5002(07)70156-3PMID 17008700
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Positron-emission tomography and assessment of cancer therapy.

  2006cited by this paper
• Monitoring chemotherapy and radiotherapy of solid tumors

  2006cited by this paper
• Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group.

  2006cited by this paper
• Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.

  2006cited by this paper
• The role of PET in the surgical management of malignant pleural mesothelioma.

  2005cited by this paper
• Therapy response evaluation in malignant pleural mesothelioma with integrated PET-CT imaging.

  2005cited by this paper
• Advances in malignant mesothelioma.

  2005cited by this paper
• Use of PET for monitoring cancer therapy and for predicting outcome.

  2005cited by this paper
• CT, RECIST, and malignant pleural mesothelioma.

  2005cited by this paper
• Phase II trials in mesothelioma: an increasing challenge.

  2005cited by this paper
• Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques.

  2004cited by this paper
• Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma.

  2004cited by this paper
• Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.

  2004cited by this paper
• Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases.

  2004cited by this paper
• The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate

  2004cited by this paper
• Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

  2003cited by this paper
• Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.

  2003cited by this paper
• Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.

  2003cited by this paper
• Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.

  2002cited by this paper
• Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• 18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study.

  2000cited by this paper
• Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

  1999cited by this paper
• Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.

  1999cited by this paper
• Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.

  1999cited by this paper
• Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.

  1998cited by this paper
• Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases.

  1996cited by this paper
• A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.

  1995cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper
• A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.

  1965cited by this paper

• Current and Future Perspective of PET/CT in Response Assessment of Malignant Pleural Mesothelioma.

  2025cites this paper
• "Current Status of Staging and Restaging Malignant Pleural Mesothelioma".

  2025cites this paper
• FDG PET/CT for Staging and Restaging Malignant Mesothelioma.

  2022cites this paper
• La eficacia de 18F-FDG-PET/CT en el seguimiento de la progresión de la enfermedad en el mesotelioma pleural malign[[es]]The efficacy of 18F-FDG PET/CT in monitoring disease progression in malignant pleural mesothelioma.

  2022cites this paper
• "Multimodality imaging of the extrapleural space lesions".

  2021cites this paper
• The Prognostic Value of 18F-FDG PET Imaging at Staging in Patients with Malignant Pleural Mesothelioma: A Literature Review

  2021cites this paper
• "PET/CT Variants and Pitfalls in Lung Cancer and Mesothelioma".

  2021cites this paper
• Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma

  2020cites this paper
• Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells

  2020cites this paper
• PERCISTence: Strength or Stubbornness?

  2020cites this paper
• Metabolic rewiring and redox alterations in malignant pleural mesothelioma

  2019cites this paper
• Radiologic Considerations And Standardization Of Malignant Pleural Mesothelioma (MPM) Imaging Within Clinical Trials: Consensus Statement From The NCI Thoracic Malignancy Steering Committee - International Association For The Study Of Lung Cancer - Mesothelioma Applied Research Foundation Clinical T

  2019cites this paper
• A rare case of distant metastasis of primary malign pericardial mesothelioma with 18F-FDG PET/CT

  2019influential citation
• British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma

  2018cites this paper
• Intensity Modulated Radiation Therapy versus Supportive Care in Malignant Pleural Mesothelioma: A Pilot Study for Treatment Outcomes and Cost-Effective Expectations

  2018cites this paper
• The Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging in Mesothelioma

  2018cites this paper
• Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)

  2018cites this paper
• Nuclear Oncology

  2017cites this paper
• Prognostic and predictive role of [18F]fluorodeoxyglucose positron emission tomography (FDG‐PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up‐front pemetrexed‐based chemotherapy

  2017cites this paper
• Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.

  2017cites this paper
• First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma

  2017cites this paper
• Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial

  2017cites this paper
• A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma

  2017cites this paper
• Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma

  2016cites this paper
• Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature.

  2015cites this paper
• Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma

  2015cites this paper
• The potential value of volume-based quantitative PET parameters and increased bone marrow uptake for the prediction of survival in patients with malignant pleural mesothelioma

  2015cites this paper
• Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?

  2015cites this paper
• New High Affinity Monoclonal Antibodies Recognize Non-Overlapping Epitopes On Mesothelin For Monitoring And Treating Mesothelioma

  2015cites this paper
• Management of malignant pleural mesothelioma-The European experience.

  2014cites this paper
• Malignant pleural mesothelioma: role of CT, MRI, and PET/CT in staging evaluation and treatment considerations.

  2013influential citation
• Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

  2013cites this paper
• Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma.

  2013cites this paper
• FDG PET/CT in the management of primary pleural tumors and pleural metastases.

  2013cites this paper
• Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.

  2013cites this paper
• Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma.

  2012cites this paper
• PET Scan Contribution in Chest Tumor Management: A Systematic Review for Thoracic Surgeons

  2012cites this paper
• Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma.

  2012cites this paper
• FDG PET/CT Response Evaluation in Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Chemotherapy

  2012cites this paper
• The role of FDG PET-CT in differential diagnosis of pleural pathologies.

  2012cites this paper
• Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.

  2012cites this paper
• Spectrum of malignant pleural and pericardial disease on FDG PET/CT.

  2012cites this paper
• Malignant pleural mesothelioma: factors influencing the prognosis.

  2012cites this paper
• Monitoring of chemotherapy response in malignant pleural mesothelioma using fluorodeoxyglucose positron emission tomography.

  2012cites this paper
• CD147 immunohistochemistry discriminates between reactive mesothelial cells and malignant mesothelioma

  2012cites this paper
• Clinical and biologic prognostic factors in malignant pleural mesothelioma

  2012cites this paper
• An In Vivo Platform for Tumor Biomarker Assessment

  2011cites this paper
• Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer

  2011cites this paper
• Advances in the biology of malignant pleural mesothelioma.

  2011cites this paper
• The role of postoperative radiotherapy after resection of stage III thymoma.

  2011cites this paper
• Intensity-Modulated Radiotherapy After Extrapleural Pneumonectomy in the Combined-Modality Treatment of Malignant Pleural Mesothelioma

  2011cites this paper
• A Multimodality Imaging Review of Malignant Pleural Mesothelioma Response Assessment.

  2011cites this paper
• [F]fluorodeoxyglucose positron emission tomography in thymic epithelial tumors

  2011cites this paper
• eComment: What is the best way to diagnose and stage malignant pleural mesothelioma?

  2011cites this paper
• 18F-FDG uptake on PET helps predict outcome and response after treatment in unresectable thymic epithelial tumors

  2011cites this paper
• Current Evidence Base of FDG-PET/CT Imaging in the Clinical Management of Malignant Pleural Mesothelioma: Emerging Significance of Image Segmentation and Global Disease Assessment

  2011cites this paper
• Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?

  2011cites this paper
• Novel molecular imaging in lung and pleural diseases

  2011cites this paper
• Investigation of a unilateral pleural effusion in adults: British Thoracic Society pleural disease guideline 2010

  2010cites this paper
• Volume-Based Parameter of 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Prediction of Therapeutic Response and Prognostic Implications

  2010cites this paper
• Integrated Positron Emission Tomography-Computed Tomography Does Not Accurately Stage Intrathoracic Disease of Patients Undergoing Trimodality Therapy for Malignant Pleural Mesothelioma

  2010cites this paper
• Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage and Changes in Tumor Burden

  2010cites this paper
• Imaging of the Pleura

  2010cites this paper
• Assessment of Therapy Responses and Prediction of Survival in Malignant Pleural Mesothelioma Through Computer-Aided Volumetric Measurement on Computed Tomography Scans

  2010cites this paper
• A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions.

  2010cites this paper
• Epidemiology of mesothelioma in Egypt. A ten-year (1998-2007) multicentre study

  2010cites this paper
• Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma.

  2010cites this paper
• A Phase I Trial of Repeated Intrapleural Adenoviral-mediated Interferon-β Gene Transfer for Mesothelioma and Metastatic Pleural Effusions.

  2010cites this paper
• Mesothelioma.

  2010cites this paper
• Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma.

  2010cites this paper
• Imaging of the pleura

  2010cites this paper
• Second-line treatment for malignant pleural mesothelioma.

  2010cites this paper
• Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group.

  2010cites this paper
• A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters

  2010cites this paper
• Role of Integrated 18-Fluorodeoxyglucose Position Emission Tomography-Computed Tomography in Patients Surveillance after Multimodality Therapy of Malignant Pleural Mesothelioma

  2010cites this paper
• Future developments in the management of malignant pleural mesothelioma

  2009cites this paper
• Current trends in radiologic management of malignant pleural mesothelioma.

  2009cites this paper
• Early evaluation of the effects of chemotherapy with longitudinal FDG small-animal PET in human testicular cancer xenografts: early flare response does not reflect refractory disease

  2009cites this paper
• Prognostic Value of 18F-FDG PET/CT in Patients with Malignant Pleural Mesothelioma

  2009cites this paper
• Lymph node dissection in primary intrahepatic malignant mesothelioma: case report and implications for diagnosis and therapy

  2009cites this paper
• Malignant Pleural Mesothelioma Presenting as Low Back Pain: Diagnosed by Bone Scan Coordinating With F-18 FDG PET/CT

  2009cites this paper
• Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related Benign Pleural Disease: An Observational Pilot Study

  2009cites this paper
• Is FDG-PET/CT useful for managing malignant pleural mesothelioma?

  2009cites this paper
• 18F‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma *

  2009cites this paper
• Measuring response with FDG-PET: methodological aspects.

  2009cites this paper
• CT appearances of pleural tumours.

  2009cites this paper
• Malignant pleural mesothelioma.

  2009cites this paper
• FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after the Initial Cycle of Neoadjuvant Chemotherapy in High-Grade Soft-Tissue Sarcomas

  2009cites this paper
• Early detection of malignant pleural mesothelioma through measurement of soluble mesothelin‐related protein and positron emission tomography

  2009cites this paper
• [PET/CT in breast cancer: an update].

  2009cites this paper
• Molecular probes for the in vivo imaging of cancer.

  2009cites this paper
• From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

  2009cites this paper
• Advances in the systemic therapy of malignant pleural mesothelioma

  2008cites this paper
• Current concepts in malignant pleural mesothelioma

  2008cites this paper
• Prise en charge diagnostique et thérapeutique du mésothéliome pleural malin en 2008

  2008cites this paper
• Current therapies for malignant pleural mesothelioma

  2008cites this paper
• Current state and future directions of pleural mesothelioma imaging.

  2008cites this paper
• Mesothelioma and Asbestos-Related Pleural Diseases

  2008cites this paper
• PET, CT, and MR Imaging for Assessment of Thoracic Malignancy: Structure Meets Function.

  2008cites this paper
• Early Chemotherapy Response Evaluation in Tumors by 99mTc-DTPA-DG

  2008cites this paper